In November 2021 we announced the decision to widen access to adalimumab and award Principal Supply to Amgevita, a citrate-free biosimilar adalimumab. Amgevita will be listed in the Pharmaceutical Schedule from 1 March 2022.
What does this change mean
From 1 March 2022, most patients currently using Humira will need to transition to Amgevita.
There are some key actions that healthcare professionals can take to support this change.
You can find more information about this change, and what it means for you, on the Pharmac website.
Resources are available to support you and your patients with this change:
He Ako Hiringa: Biological Medicines Resource Hub
He Ako Hiringa: Transition to adalimumab biosimilar
More resources will be released in the coming weeks. We will continue to update the Pharmac website with links to resources to support this change as they become available.
Please share this information
We want to make sure everyone who needs to know about these changes is aware of them. Please share this information with your colleagues.
We want to extend our thanks to you and your colleagues for supporting people with this change.
Click here for the mailer
Ngā mihi nui,
Chief Medical Officer | Tumu Whakarae Haumanu
Extra support is being made available to Māori and Pacific communities as they continue to face the impact of the current Omicron outbreak.This extra support is in addition to the Care in the Community boost the Government announced last week to help all families who need to self-isolate, as well as the social service organisations and community providers working hard to support them.
Omicron is likely to disproportionately affect Māori and Pasifika communities, and the Government is committed to making sure vulnerable whanau received the support and care they deserve.
Click here to read the full update
23 February 2022
Got some news to share with the group? Email email@example.com
Hi Lisa,Message from the chair of HiNZ-NMIWelcome to 2022!
We are resilient in healthcare, but I have had a sense of ‘oh dear, here we go again….’ However we are very used to just ‘rolling with it’ and ‘going with the flow’. What other choice do we have?
Healthcare is a rollercoaster at the moment and there are many ebbs and flows on that ride. The use of technology in healthcare continues to make its presence felt within this pandemic (my Dad has even succumbed to getting a smart phone). If we take a look from a more positive point of view, that is certainly something that we can take away from the experiences we have all had over the last two years. When this is all over (note I specifically said ‘when’ not ‘if’) we will have advanced our healthcare services and achieved greater connectivity and technologically competent practitioners.
Click here to read the full Newsletter
he Government is standing up additional support to help people and whānau who have to self-isolate access the services they need as Omicron cases start to ramp up and more New Zealanders are affected by the virus.
With Omicron cases increasing it is important whānau have the support they need to self-isolate and stop the spread of the virus.
In recent weeks we have seen an over 60 percent increase in people with no existing MSD relationship needing support, so it is timely for us to be increasing the welfare support provided through the Care in Community approach.
Click here for more information
Good afternoon, on behalf of Dr Stephen du Toit, Pathologist and John Woodford, Lead of Specialty Biochemistry as attached.
We are grateful if you could please ensure all relevant persons in your organisation are advised.
Click here for the full update
It has been a very busy start to the year with vaccinations for 5-11 year olds, boosters, red traffic lights and Omicron in the community. Great work is going on around the country, thanks to all our wonderful vaccinators.
We have quite a few updates for you to support this work:
Click here for your February Toolkit
Ngā mihi nui
Immunisation Advisory Centre team
Write something about yourself. No need to be fancy, just an overview.